CVS Health Reports Worsening Shortages of Estradiol Injections
CVS Health stated that manufacturers have struggled to supply certain strengths of estradiol injections, with the situation deteriorating in recent weeks.
Stocks · News reference
CVS Health is terminating its SilverScript Choice stand-alone prescription drug plan in 13 regions for the 2027 coverage year, impacting approximately 950,000 enrollees.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
CVS Health stated that manufacturers have struggled to supply certain strengths of estradiol injections, with the situation deteriorating in recent weeks.
The U.S. Department of Labor is expected to introduce new regulations requiring Pharmacy Benefit Managers (PBMs) to disclose detailed information regarding their fees and revenue sources to employer clients.
CVS Health is in discussions with Medicare to broaden the scope of pharmacist-led chronic disease management and improve patient access to high-cost GLP-1 medications.